Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients
<i>Background and Objectives</i>: Lung cancer is the second most common cancer in the world. Non-small-cell lung carcinoma (NSCLC) makes up 85% of all lung cancer cases and the majority of patients are diagnosed when the cancer is advanced. Over the years, many anticancer drugs have been...
Guardado en:
Autores principales: | Ting Yoon Kwan, Ezharul Hoque Chowdhury |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a7368c147106496abfb1c43ebaa63734 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Treatment of advanced small cell lung cancer. Clinical case and literature review
por: Konstantin V. Menshikov, et al.
Publicado: (2021) -
Decrease in Blood Neutrophil-to-Lymphocyte Ratio Indicates Better Survival After Neoadjuvant Chemotherapy in Patients With Advanced Gastric Cancer
por: Ziyi Liu, et al.
Publicado: (2021) -
Pemetrexed-based first-line chemotherapy had particularly prominent objective response rate for advanced NSCLC: A network meta-analysis
por: Lv Yuankai, et al.
Publicado: (2021) -
Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer
por: Minami S, et al.
Publicado: (2016) -
Immunohistochemistry for Thymidine Kinase-1 (TK1): A Potential Tool for the Prognostic Stratification of Breast Cancer Patients
por: Giuseppe Nicolò Fanelli, et al.
Publicado: (2021)